Tesofensin Research Guide Ireland

Overview

Tesofensin is a small-molecule triple monoamine reuptake inhibitor — it is not a peptide, but is included in peptide-adjacent research contexts due to its relevance to metabolic and weight-management research. It was originally developed by NeuroSearch (Denmark) for Parkinson's disease and Alzheimer's disease, where its effect on dopamine, noradrenaline, and serotonin reuptake was investigated for cognitive and motor symptom research. During those trials, an unexpected and consistent finding of significant weight loss in study participants redirected research interest toward obesity. Following NeuroSearch's discontinuation of the compound's neurological research programme, Danish biotech Saniona acquired rights to tesofensin and has continued its development specifically for obesity research, including a modified sustained-release formulation and combination approaches. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔
Observational	✗
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗ (not approved for obesity as of most recent published trial data; ongoing development)

Mechanism of Action

Tesofensin inhibits the reuptake of three monoamine neurotransmitters — dopamine, noradrenaline, and serotonin — at their respective presynaptic transporters (DAT, NET, and SERT), increasing their availability in synaptic clefts within the central nervous system. This triple reuptake inhibition profile distinguishes it from single- or dual-mechanism appetite suppressants, and is theorised to act on hypothalamic appetite-regulating circuits and mesolimbic reward pathways associated with food intake behaviour. The weight-loss effect observed in the original Parkinson's and Alzheimer's trials is believed to arise primarily from appetite suppression (reduced caloric intake) rather than a significant increase in energy expenditure, based on data from the Phase II obesity trial designed specifically to characterise this effect. Its multi-transporter mechanism is mechanistically distinct from GLP-1 receptor agonists, amylin analogues, and GHRPs, situating tesofensin within a separate pharmacological class for obesity research (centrally acting monoamine reuptake inhibitors).

Research Areas & Reported Effects

Original Neurological Research (Parkinson's/Alzheimer's)

Tesofensin was initially studied for its potential to improve motor symptoms in Parkinson's disease and cognitive symptoms in Alzheimer's disease, based on its dopaminergic and noradrenergic activity. These trials did not demonstrate sufficient efficacy for the neurological indications to support continued development in that direction, but recorded an unanticipated and reproducible weight-loss signal in participants.

Phase II Obesity Trial (Astrup et al., 2008)

The pivotal Phase II obesity trial, published by Astrup and colleagues in The Lancet in 2008, randomised obese participants to placebo or tesofensin (0.25 mg, 0.5 mg, or 1.0 mg daily) for 24 weeks. The 1.0 mg dose group reported a mean weight loss of approximately 10.6% of body weight, substantially larger than typical weight-loss medications available at the time, alongside reported reductions in waist circumference and improvements in some cardiometabolic markers.

Continued Development by Saniona

Following NeuroSearch's exit from the neurological indications, Saniona has continued researching tesofensin for obesity, including a modified sustained-release ("TESOMET" — tesofensin plus metoprolol, the latter added to mitigate heart-rate increases observed with tesofensin alone) combination aimed at retaining the appetite-suppressing effect while addressing cardiovascular tolerability signals seen in earlier trials.

Research Data Summary

Study / Model	Reported Effect
Astrup A et al. 2008, Phase II Obesity RCT (The Lancet)	Reported ~10.6% mean weight loss at 24 weeks with 1.0 mg daily dose versus placebo in obese adults.
Original Parkinson's/Alzheimer's Trials (NeuroSearch)	Insufficient efficacy signal for neurological endpoints; incidental but consistent weight-loss finding prompted redirection of the research programme.
TESOMET (tesofensin + metoprolol) Phase II (Saniona)	Reported weight loss with mitigated heart-rate elevation compared with tesofensin monotherapy in trial populations, including hypothalamic obesity research cohorts.
Preclinical Rodent Feeding Behaviour Studies	Reported reduced food intake consistent with central monoamine reuptake inhibition mechanism, supporting the appetite-suppression hypothesis over an energy-expenditure mechanism.

Stack Combinations Studied

• Tesofensin + Metoprolol (TESOMET) → Research rationale: Metoprolol (a beta-blocker) was combined with tesofensin specifically to counteract the heart-rate increase observed with tesofensin monotherapy, allowing continued research into the appetite-suppressing effect with improved cardiovascular tolerability.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Low-Dose Trial Protocol (as trialled)	0.25 mg	24 weeks	Once daily, oral	Lowest dose arm in Astrup et al. 2008 Phase II trial.
Standard Trial Protocol (as trialled)	0.5 mg	24 weeks	Once daily, oral	Mid-dose arm; reported meaningful weight loss versus placebo.
High-Dose Trial Protocol (as trialled)	1.0 mg	24 weeks	Once daily, oral	Highest efficacy signal (~10.6% weight loss) but also highest rate of heart-rate/blood-pressure related findings.

Observed Side Effects in Research

• Increased heart rate (dose-dependent, notable finding across trials)
• Dry mouth
• Insomnia
• Constipation
• Nausea
• Mild increases in blood pressure at higher doses

The cardiovascular signal (elevated heart rate) observed in the Astrup et al. 2008 trial was a key factor prompting the later development of the TESOMET combination, which pairs tesofensin with a beta-blocker specifically to mitigate this effect.

Compound Data

CAS Number

402713-80-8 (tesofensin base); commonly researched as the citrate/tartrate salt in trials

Molecular Formula

C₁₇H₂₂ClNO

Molecular Weight

Approximately 291.8 g/mol (free base)

Half-Life

Long — approximately 8-16 days at steady state, supporting once-daily oral dosing with slow accumulation

Synonyms

NS2330, TE (Saniona/NeuroSearch research code), component of TESOMET (with metoprolol)

Research Classification

Triple Monoamine Reuptake Inhibitor (Dopamine/Noradrenaline/Serotonin), Centrally Acting Appetite Suppressant

Scientific References

• [Astrup A et al. 2008] — Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. — The Lancet — [Human RCT, Phase II]
• [Astrup A et al. 2008b] — Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog liraglutide (comparative obesity trial context citing tesofensin mechanism class)] — [Contextual reference, human RCT obesity class]
• [Sjödin A et al. 2010] — The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. — International Journal of Obesity — [Human RCT, mechanistic sub-study]
• [Saniona A/S, TESOMET Clinical Trial Disclosures] — Phase II trial results for TESOMET in obesity and hypothalamic obesity. — Company clinical trial reports — [Human RCT]

Research base note: Tesofensin's obesity research base rests substantially on one pivotal, well-cited Phase II trial (Astrup et al. 2008) plus follow-on TESOMET combination work by Saniona. It has not completed Phase III obesity trials or gained regulatory approval for weight management as of the most recent published data. The cardiovascular tolerability signal identified in the original trial remains a central research consideration.

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*